Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Genocea Biosciences's share price for the quarter that ended in Mar. 2022 was $1.25. Genocea Biosciences's Shares Outstanding (EOP) for the quarter that ended in Mar. 2022 was 58.73 Mil. Therefore, Genocea Biosciences's market cap for the quarter that ended in Mar. 2022 was $73.42 Mil.
Genocea Biosciences's quarterly market cap
declined
from Sep. 2021 ($109.87 Mil) to Dec. 2021 ($67.54 Mil) but then
increased
from Dec. 2021 ($67.54 Mil) to Mar. 2022 ($73.42 Mil).
Genocea Biosciences's annual market cap
increased
from Dec. 2019 ($56.83 Mil) to Dec. 2020 ($128.31 Mil) but then
declined
from Dec. 2020 ($128.31 Mil) to Dec. 2021 ($67.54 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Genocea Biosciences's Enterprise Value for Today is $0.00 Mil.
Genocea Biosciences Market Cap Historical Data
The historical data trend for Genocea Biosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Genocea Biosciences's Market Cap
For the Biotechnology subindustry, Genocea Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genocea Biosciences's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genocea Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Genocea Biosciences's Market Cap falls into.
Genocea Biosciences Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Genocea Biosciences's Market Cap for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genocea Biosciences (OTCPK:GNCAQ) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Genocea Biosciences Market Cap Related Terms
Thank you for viewing the detailed overview of Genocea Biosciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Genocea Biosciences (Genocea Biosciences) Business Description
Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns a pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GNCAQ has been successfully added to your 